Results From the Loire-Ardèche-Drôme-Isère-Puy-de-Dôme (LADIP) Trial on Atrial Flutter, a Multicentric Prospective Randomized Study Comparing Amiodarone and Radiofrequency Ablation After the First Episode of Symptomatic Atrial Flutter

• Published in: Circulation (New York, N.Y.) N.Y.), 2006-10, Vol.114 (16), p.1676-1681
• Main Authors: Da Costa, Antoine, Thévenin, Jérôme, Roche, Frédéric, Romeyer-Bouchard, Cécile, Abdellaoui, Loucif, Messier, Marc, Denis, Lucien, Faure, Emmanuel, Gonthier, Régis, Kruszynski, Georges, Pages, J. Marie, Bonijoly, Serge, Lamaison, Dominique, Defaye, Pascal, Barthélemy, J. Claude, Gouttard, Thierry, Isaaz, Karl
• Format: Article
• Language: English
• ISSN: 0009-7322; 1524-4539
• DOI: 10.1161/CIRCULATIONAHA.106.638395

Background— There is no published randomized study comparing amiodarone therapy and radiofrequency catheter ablation (RFA) after only 1 episode of symptomatic atrial flutter (AFL). The aim of the Loire-Ardèche-Drôme-Isère-Puy-de-Dôme (LADIP) Trial of Atrial Flutter was 2-fold: (1) to prospectively compare first-line RFA (group I) versus cardioversion and amiodarone therapy (group II) after only 1 AFL episode; and (2) to determine the impact of both treatments on the long-term risk of subsequent atrial fibrillation (AF). Methods and Results— From October 2002 to February 2006, 104 patients (aged 78±5 years; 20 women) with AFL were included, with 52 patients in group I and 52 patients in group II. The cumulative risk of AFL or AF was interpreted with the use of Kaplan-Meier curves and compared by the log-rank test. Clinical presentation, echocardiographic data, and follow-up were as follows: age (78.5±5 versus 78±5 years), history of AF (27% versus 21.6%); structural heart disease (58% versus 65%), left ventricular ejection fraction (56±14% versus 54.5±14%), left atrial size (43±7 versus 43±6 mm), mean follow-up (13±6 versus 13±6 months; P =NS), recurrence of AFL (3.8% versus 29.5%; P